{"id":"NCT00915551","sponsor":"Peplin","briefTitle":"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","officialTitle":"A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIb)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2009-06-08","resultsPosted":"2012-03-16","lastUpdate":"2015-03-06"},"enrollment":278,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"PEP005 (Ingenol Mebutate) gel, 0.015%","otherNames":[]},{"type":"DRUG","name":"Vehicle Gel","otherNames":[]}],"arms":[{"label":"PEP005 (Ingenol Mebutate) gel","type":"EXPERIMENTAL"},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.","primaryOutcome":{"measure":"Complete Clearance of Actinic Keratoses (AK) Lesions","timeFrame":"baseline and 57 days","effectByArm":[{"arm":"PEP005 (Ingenol Mebutate) Gel, 0.015%","deltaMin":67,"sd":null},{"arm":"Vehicle Gel","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":21,"countries":["United States","Australia"]},"refs":{"pmids":["22417254"],"seeAlso":["http://www.fda.gov","http://www.tga.gov.au"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":142},"commonTop":["Application site pain","Application site pruritus"]}}